MA32062B1 - Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments - Google Patents

Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments

Info

Publication number
MA32062B1
MA32062B1 MA33060A MA33060A MA32062B1 MA 32062 B1 MA32062 B1 MA 32062B1 MA 33060 A MA33060 A MA 33060A MA 33060 A MA33060 A MA 33060A MA 32062 B1 MA32062 B1 MA 32062B1
Authority
MA
Morocco
Prior art keywords
trisolium
drugs
produced
salts act
par1
Prior art date
Application number
MA33060A
Other languages
Arabic (ar)
English (en)
Inventor
Uwe Heinelt
Volkmar Wehner
Matthias Herrmann
Karl Schoenafinger
Henning Steinhagen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32062B1 publication Critical patent/MA32062B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule (i) à activité antithrombotique, qui inhibent en particulier le récepteur 1 activé par une protéase (par1), des procédés de production de ces composés et leur utilisation en tant que médicaments.
MA33060A 2008-02-05 2010-08-04 Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments MA32062B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290114 2008-02-05
PCT/EP2009/000407 WO2009097971A1 (fr) 2008-02-05 2009-01-23 Sels de triazolium en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments

Publications (1)

Publication Number Publication Date
MA32062B1 true MA32062B1 (fr) 2011-02-01

Family

ID=39816936

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33060A MA32062B1 (fr) 2008-02-05 2010-08-04 Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments

Country Status (19)

Country Link
US (2) US8198272B2 (fr)
EP (1) EP2240486B1 (fr)
JP (1) JP5577259B2 (fr)
KR (1) KR20100120139A (fr)
CN (1) CN101981035B (fr)
AU (1) AU2009211888B2 (fr)
BR (1) BRPI0907487A2 (fr)
CA (1) CA2713551C (fr)
CO (1) CO6311103A2 (fr)
ES (1) ES2553588T3 (fr)
IL (1) IL207203A0 (fr)
MA (1) MA32062B1 (fr)
MX (1) MX2010007893A (fr)
MY (1) MY148732A (fr)
NZ (1) NZ587142A (fr)
PL (1) PL2240486T3 (fr)
RU (1) RU2494100C2 (fr)
WO (1) WO2009097971A1 (fr)
ZA (1) ZA201004468B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
CN102961382B (zh) * 2012-11-28 2014-07-16 玉林师范学院 一种骨肉瘤细胞抑制剂及制备方法
TW201730189A (zh) 2015-12-23 2017-09-01 吉斯藥品公司 激酶抑制劑
CN112979655A (zh) 2019-12-16 2021-06-18 上海赛默罗生物科技有限公司 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺
CN115385853B (zh) * 2022-10-17 2024-02-02 山东友道化学有限公司 一种2-肼基-3-氯吡啶的生产方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) * 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
LT3200B (en) * 1992-03-18 1995-03-27 Takeda Chemical Industries Ltd Triazolopyridazine methodfor production thereof and use
CA2198019A1 (fr) * 1994-09-16 1996-03-21 Takeda Chemical Industries, Ltd. Methode et intermediaires pour la preparation de triazolopyridines; utilisation comme medicaments
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
RU2270192C2 (ru) * 2001-04-19 2006-02-20 Эйсай Ко., Лтд. Производные 2-иминопирролидина
CA2448509A1 (fr) 2001-05-25 2002-12-05 Mochida Pharmaceutical Co., Ltd. Derives de 4-hydroxypiperidine a activite analgesique
EP1439178A4 (fr) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
EP1982984B1 (fr) 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Antagonistes de récepteur de thrombine tricyclique et compositions pharmaceutiques les contenant
EP1602646A4 (fr) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd Procedes de production de derive de benzamidine cyclique
TW200531688A (en) * 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
WO2006051648A1 (fr) 2004-11-09 2006-05-18 Eisai R & D Management Co., Ltd. Médicament contenant un antagoniste du récepteur de la thrombine au titre de principe actif et destiné au traitement d'angiospasmes causés par une hémorragie sous-arachnoïdienne
RS55630B1 (sr) * 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2009097973A2 (fr) * 2008-02-05 2009-08-13 Sanofi-Aventis Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments
WO2009097972A1 (fr) * 2008-02-05 2009-08-13 Sanofi-Aventis Dérivés de sf5 en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments
US8324241B2 (en) * 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
WO2009126861A2 (fr) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés de triazolopyridine utiles en tant qu'inhibiteurs de dgat1
ES2624828T3 (es) * 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros

Also Published As

Publication number Publication date
HK1149012A1 (en) 2011-09-23
ZA201004468B (en) 2011-03-30
KR20100120139A (ko) 2010-11-12
ES2553588T3 (es) 2015-12-10
CA2713551C (fr) 2016-06-14
RU2494100C2 (ru) 2013-09-27
AU2009211888B2 (en) 2013-06-20
CN101981035A (zh) 2011-02-23
WO2009097971A1 (fr) 2009-08-13
CA2713551A1 (fr) 2009-08-13
NZ587142A (en) 2012-04-27
AU2009211888A1 (en) 2009-08-13
US20120208805A1 (en) 2012-08-16
EP2240486A1 (fr) 2010-10-20
US8853206B2 (en) 2014-10-07
CO6311103A2 (es) 2011-08-22
IL207203A0 (en) 2010-12-30
US8198272B2 (en) 2012-06-12
EP2240486B1 (fr) 2015-09-09
MY148732A (en) 2013-05-31
MX2010007893A (es) 2010-08-09
RU2010136941A (ru) 2012-03-20
PL2240486T3 (pl) 2016-02-29
US20110034452A1 (en) 2011-02-10
BRPI0907487A2 (pt) 2015-07-14
CN101981035B (zh) 2013-08-28
JP5577259B2 (ja) 2014-08-20
JP2011511017A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
HRP20090235A2 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
MA37886B1 (fr) Nouvelles pyridinones bicycliques
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
UY30282A1 (es) Compuestos quimicos
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MX2010009462A (es) Derivados de indazol.
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
TW200740814A (en) Compounds
MA35305B1 (fr) Nouveaux acides pipéridinylmonocarboxyliques à titre d'agonistes des récepteurs de s1p1